CN1 / Curon Biopharma - LARVOL DELTA

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1/2 | N=7 | Terminated | Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd | N=78 ➔ 7 | Trial completion date: Jul 2023 ➔ Sep 2022 | Recruiting ➔ Terminated; Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.

Combination therapy • Enrollment change • Trial completion date • Trial termination • Hematological Malignancies • Oncology

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 (clinicaltrials.gov) - P1; N=13; Completed; Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd; Recruiting ➔ Completed; N=22 ➔ 13; Trial completion date: Apr 2022 ➔ Oct 2021; Trial primary completion date: Feb 2022 ➔ Oct 2021

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1/2; N=78; Recruiting; Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Hematological Malignancies • Oncology • MRI

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1/2; N=78; Not yet recruiting; Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd

Clinical • Combination therapy • New P1/2 trial • Hematological Malignancies • Oncology

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 (clinicaltrials.gov) - P1; N=22; Recruiting; Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 (clinicaltrials.gov) - P1; N=22; Not yet recruiting; Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd

Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology